NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults

NCT07019909

CompletedPhase 1

Sponsor: Pfizer

Conditions: Pneumococcal Disease

Interventions: 20vPnC, 13vPnC

Countries: China

This Phase 1, randomized, double-blind, third-party-unblinded study will be conducted at investigational sites in China. The purpose of the study is to learn about the safety and immune response of 20vPnC and 13vPnC in Chinese adults 50 years of age and older who did not receive any of pneumococcal vaccine in the past

Eligibility overview

Sex: ALL

Age: 50 Years to —

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Key inclusion criteria:

1.Generally healthy adults including those with preexisting stable disease determined to be eligible based on clinical assessment, medical history and clinical judgment.

Key exclusion criteria:

1. History of microbiologically-proven invasive disease caused by Streptococcus pneumoniae
2. Previous vaccination with any licensed or investigational pneumococcal vaccine or planned receipt through study participation.

Locations (3)

Hangzhou, Zhejiang, China
Kaihua, Zhejiang, China
Quzhou, Zhejiang, China